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Angiogenesis in glioblastoma: just another
moving target?
Inhibition of angiogenesis as a concept experienced a renaissance
in neuro-oncology in 2009. Based on encouraging phase II data
suggesting increased response rates and improved quality of life,
including a corticosteroid-sparing effect (Friedman et al., 2009;
Kreisl et al., 2009), bevacizumab—an antibody that targets vas-
cular endothelial-derived growth factor (VEGF)—was approved for
the treatment of recurrent glioblastoma in the US and, for
example, in Switzerland; but not throughout the European
Union (Weller and Stupp, 2009). Further, the results of a 2:1:2
randomized trial comparing the VEGF receptor antagonist, cedira-
nib (Batchelor et al., 2007), with the alkylating agent lomustine,
and the combination of cediranib and lomustine in patients with
recurrent glioblastoma are to be presented at the American Society
of Clinical Oncology meeting in June 2010. Finally, not only bev-
acizumab (and probably soon cediranib, too), but also another
anti-angiogenic agent, the integrin antagonist cilengitide, are cur-
rently being evaluated in registration trials for patients with newly
diagnosed glioblastoma (Stupp et al., 2010).
Theoretical support for the therapeutic approach of angiogen-
esis inhibition in glioblastoma stems from the idea that the endo-
thelial cell is the only stable, reliable element in an increasingly
heterogenous and chaotic tumour microenvironment. Genetic in-
stability of glioma cells might drive rapid selection processes
resulting in the generation of multiple and diverse resistant
tumour cell clones. In contrast, it has commonly been assumed
that (true) endothelial cells, which are non-neoplastic host cells
recruited by the growing tumours, would be resistant to the devel-
opment of resistance, because of their stable genetic phenotype.
Yet, clinical experience has already taught us that such views are
over-simplified.
First, not all vessel formation in glioma depends on VEGF. This is
apparent from the rate of responding patients defined by classical
neuroradiological outcome criteria of 30–50% (Batchelor et al.,
2007; Friedman et al., 2009; Kreisl et al., 2009). Whilst these data
should be welcomed as promising, it must not escape our notice that
at least half of glioblastomas do quite well in the presence of bev-
acizumab or cediranib, indicating that not all glioblastoma-related
angiogenesis is strictly dependent on VEGF. Second, the responses
to anti-angiogenic agents targeting VEGF are commonly transient,
suggesting that there are effective escape mechanisms for blood
vessel formation, contradicting the wishful thinking of endothelial
resistance to the development of resistance to targeted anti-angio-
genic therapy. In fact, numerous other molecules, including other
VEGF-family members as well as placenta-derived, hepatocyte and
fibroblast growth factor, are implicated in the primary or acquired
resistance to VEGF-antagonistic treatments.
Against this background, in the current issue of Brain, El Hallani
et al. (2010) address a largely neglected mechanism by which
gliomas maintain vascular perfusion—the formation of vessel-like
structures by the tumour cells themselves, referred to as ‘vasculo-
genic mimicry of the tubular type’. They identify a subset of glio-
blastomas characterized by ‘blood vessels’ that are lined by
non-endothelial cells. This interpretation is based on the presence
of collagen IV, a marker of blood vessel basement membranes, in
the absence of the expression of CD34, a universal marker for
endothelial cells. To support the idea that the vessel-lining cells
are tumour cells, the authors demonstrate the amplification of
epidermal growth factor receptor (EGFR) in these cells, in a
tumour known to harbour the molecular phenotype of EGFR
amplification. Some of the tumour cells express smooth muscle
actin, indicating that these have trans-differentiated into vascular
smooth muscle-like cells. Intriguingly, the authors provide one
example of a tissue section where there appears to be an anasto-
mosis between an endothelially lined and a tumour-derived
‘vessel’. Finally, the authors analyse the subpopulation of
glioma-initiating cells by CD133 sorting from two tumours, one
with and one without putative tumour-derived blood vessels.
CD133+ cells from the former tumour generate vessel-like struc-
tures in tube formation assays, whereas the latter do not. An ex-
pression of endothelium-associated genes was observed in both
populations of glioma-initiating cells. These observations lead the
authors to propose that the subpopulation of glioma-initiating cells
may even possess the plasticity to form blood vessels. Taken as a
whole, this study indicates that some glioblastomas may grow in
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the absence of endothelial cell recruitment, suggesting that they
may exhibit primary refractoriness to therapeutic approaches tar-
geting VEGF. Clearly, further studies are needed to clarify the
overall frequency of this phenotype and its contribution to the
perfusion of glioblastomas in a larger sample of tumours.
The introduction of novel anti-angiogenic agents has already
imposed new challenges on clinical neuro-oncologists, some of
which have been faced and almost solved whereas others require
new approaches. Thus, the response criteria devised by
Macdonald and colleagues (1990) required modification in order
to rely less on contrast enhancement, to include the necessity for
confirmation of the response and to consider tumour extensions
on T2-weighted magnetic resonance imaging (Van den Bent et al.,
2009). The latter became necessary when it was recognized that
some patients treated with bevacizumab exhibit altered patterns of
recurrence reminiscent of gliomatosis cerebri, attributed to a
change from vessel- and VEGF-dependent to growth that is inde-
pendent of each (Norden et al., 2008). Future clinical trials will
aim to identify prospective biomarkers associated with response or
lack of response to anti-angiogenic agents. But it is now clear that
such analyses should start with a careful neuropathological and
neuroradiological characterization of the pre-treatment vascular-
ization of these tumours.
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